Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer. (OlympiA)
https://www.facingourrisk.org/research-clinical-trials/study/19/olympia-olaparib-adjuvant-therapy-for-brca-related-breast-cancer
Clinicaltrials.gov identifier:
NCT02032823 (https://clinicaltrials.gov/show/NCT02032823)
Study Contact Information:
- Principal Investigators: Andrew Tutt, Doctor of Medicine Integrated Cancer Centre Guy's Hospital, King's College, London School of Medicine, London, UK; Bella Kaufman, Sheba Medical Center, 1 Tel Hashomer, Israel; Judy Garber, Doctor of Medicine Harvard Medical School, Center for Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston; MA; Charles Geyer, Doctor of Medicine Virginia Commonwealth University Massey Cancer Center, Richmond, VA
About the Study
The OlympiA trial is the first major study to test the PARP inhibitor olaparib (Lynparza) for people with BRCA mutation-associated breast cancer in the adjuvant setting (after surgery) for people with earlier-stage (stage 2 or stage 3) cancers. OlympiA is a phase III clinical trial looking at the safety and effectiveness of olaparib for women with stage 2 or 3 breast cancer with a BRCA mutation after they have completed standard therapy.
The OlympiA trial has now completed enrollment. Interim results from OlympiA were presented at the 2021 ASCO Annual Symposium.
This Study is Open To:
The study is no longer enrolling patients.
This Study is Not Open To:
The study is no longer enrolling patients.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.